Nataliya Uboha, MD, PhD

Hematology, Medical Oncology and Palliative Care
Associate Professor (CHS)
Clinical Science Center
600 Highland Ave K4/518
Madison WI 53792-0001
(608) 265-9966

Follow Dr. Merrins:

LinkedIn icon

Education

  • Yale University School of Medicine MD/PhD Training Program, New Haven, Connecticut – MD, PhD in Molecular Neuroscience
  • Yale New Haven Hospital – Residency in Internal Medicine
  • Smilow Cancer Hospital at Yale New Haven Hospital – Fellowship in Medical Hematology and Oncology

Professional Activities

Dr. Nataliya Uboha is a faculty member in the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine and a member of Carbone Cancer Center (UWCCC). She is a Faculty Leader for the Early Phase Oncology Therapeutics Program at UWCCC. As a medical oncologist, she specializes in treating patients with GI malignancies and focuses on gastroesophageal cancers. She has extensive clinical research experience, particularly emphasizing phase 1 and biomarker-based clinical studies. Dr. Uboha has several regional and national leadership roles. She is a Chair of the ECOG-ACRIN Upper GI working group and a Co-Chair of the National Cancer Institute Upper GI Taskforce. Dr. Uboha is a member of the NCCN Guidelines Committee for esophageal and gastric cancers. Dr. Uboha also has several roles with the American Society of Clinical Oncology (ASCO), serving as a scientific committee track chair for the 2025 ASCO Annual Meeting and as a member of the ASCO guidelines committee for upper GI cancers.

Clinical Specialties

Dr. Uboha’s clinical interests include gastrointestinal cancers, with a particular emphasis on hepatobiliary and gastroesophageal cancers.

Research Interests

Her research focuses on developing early-phase and biomarker-based clinical trials for patients with gastrointestinal malignancies. She has significant clinical trial experience, serving as a principal investigator on multiple investigator-initiated and industry-sponsored studies. She is actively part of the UW Carbone Cancer Center Phase 1 group. Dr. Uboha also co-leads the Basket Disease Oriented Team (DOT), which focuses on biomarker-based trials across disease types.